HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Epoetin alfa 40000 U once weekly and intravenous iron supply in solid tumor patients: early increase of hemoglobin level during chemotherapy.

Abstract
The objective of this observational study was the early evaluation of the impact, a week after the first administration of epoetin alfa 40000 U once weekly and i.v. dose of 62.5 mg sodium ferric gluconate for seven days in improving hemoglobin levels in cancer patients affected by mild/moderate or severe anemia during chemotherapy. Twenty patients affected by solid tumors who received epoetin alfa 40000 U once weekly and daily i.v. sodium ferric gluconate for one week were evaluated: 90% of the patients showed hemoglobin increase, with a median level of hemoglobin increase of 0.73 g/L from baseline, and 50% of them showing a hemoglobin increase > 1 gr/L. The treatment was well tolerated and no adverse event was observed. The early increase of hemoglobin level from baseline is interesting and suggestive for the possibility of achieving an adequate hemoglobin level with a short-term treatment. It is still necessary to further explore the real need of iron supplementation to maintain adequate erythropoiesis prior and during epoetin therapy.
AuthorsM Lalle, G Pistillucci, M Antimi, M D'Aprile
JournalJournal of experimental & clinical cancer research : CR (J Exp Clin Cancer Res) Vol. 24 Issue 2 Pg. 197-201 (Jun 2005) ISSN: 0392-9078 [Print] England
PMID16110751 (Publication Type: Journal Article)
Chemical References
  • Antineoplastic Agents
  • Hematinics
  • Hemoglobins
  • Recombinant Proteins
  • Erythropoietin
  • Epoetin Alfa
  • Iron
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Anemia (drug therapy, prevention & control)
  • Antineoplastic Agents (adverse effects, therapeutic use)
  • Dietary Supplements
  • Epoetin Alfa
  • Erythropoietin (administration & dosage, therapeutic use)
  • Female
  • Hematinics (therapeutic use)
  • Hemoglobins (drug effects)
  • Humans
  • Infusions, Intravenous
  • Iron (administration & dosage, metabolism, therapeutic use)
  • Male
  • Middle Aged
  • Neoplasms (blood, drug therapy)
  • Recombinant Proteins
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: